Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...
PALO ALTO, CA, USA I February 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...
EDA Explores Aircraft Battery Health Monitoring is published in Aerospace Daily & Defense Report, an Aviation Week ...
Achieving a digital transition that strengthens Europe's strategic competitiveness means addressing the persistent challenges in innovation, adoption, and technological dependency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results